Regeneron Pharmaceuticals (REGN)

$737.71 -19.02 (-2.51%)
Market Cap 80.00B
Revenue (ttm) 14.34B
Net Income (ttm) 4.50B
EPS (ttm) N/A
PE Ratio 20.77
Forward PE 21.49
Profit Margin 31.41%
Debt to Equity Ratio 0.06
Volume 492,100
Avg Vol 731,144
Day's Range N/A - N/A
Shares Out 105.72M
Stochastic %K 23%
Beta 0.41
Analysts Strong Sell
Price Target $874.15

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascul...

Industry: Biotechnology
Sector: Healthcare
Phone: 914 847 7000
Address:
777 Old Saw Mill River Road, Tarrytown, United States
Quantumup
Quantumup Mar. 27 at 12:44 PM
H.C. Wainwright reiterated $OCUL Buy/$21 $KOD $EYPT $REGN RHHBY $SRZN Here's what H.C. Wainwright had to say in its note: https://x.com/Quantumup1/status/2037510171836960935?s=20
0 · Reply
Iwannagofast1
Iwannagofast1 Mar. 27 at 4:07 AM
$REGN Hey @Johny34211 where you been hiding lil buddy? We’re at $754 through all the BS war stuff. You still living under your tiny little boulder ya donkey ? I’m still up $266 dollars a share on my second buy.
0 · Reply
SparkyReturns
SparkyReturns Mar. 26 at 6:59 PM
$BTC Public service announcement. I love BTC and these big pharma names, but here's one to check out. Up 30% and climbing. ICU Just getting started. 9 Million Market Cap. TAM in the Billions. [Read those 2 lines again] Cures the sickest of the sick. Will become standard of care in every ICU in the country. Happy hunting. $REGN $AMGN $VKTX $BMY
0 · Reply
OffHisGame88
OffHisGame88 Mar. 26 at 3:22 PM
$REGN 33% since and counting. Cheap
0 · Reply
prismmarketview
prismmarketview Mar. 25 at 2:20 PM
Gene therapy isn’t dead—it’s moving to the inner ear. Local AAV dosing for hereditary deafness cuts liver risk and COGS, and the market could top $1B by 2033. Watch $LLY and $REGN as first movers in otoferlin programs. https://prismmarketview.com/from-silence-to-signal-gene-therapies-target-hereditary-hearing-loss/
0 · Reply
Quantumup
Quantumup Mar. 24 at 12:59 PM
H.C. Wainwright⬆️ $SRZN PT to $36/reiterated at Buy. $EYPT $OCUL $FDMT $REGN RHHBY KOD Here's what H.C. Wainwright had to say in its note: https://x.com/Quantumup1/status/2036427176845640179?s=20
0 · Reply
Mnpois
Mnpois Mar. 22 at 4:11 PM
$REGN what about renergen $ASPI lol
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 22 at 3:56 PM
$REGN Regeneron Pharmaceuticals (NASDAQ: REGN) is proving that diversification can be a major advantage in biotech. With strong revenues, multiple blockbuster drugs, and a growing pipeline, this stock stands out in a volatile sector. https://biotechhealthx.com/biotech-news/heres-why-you-must-invest-in-regeneron-pharmaceuticals-regn-before-its-too-late/
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 22 at 3:21 PM
$AXSM $BNTX $EXEL $REGN $VRTX Biotech stocks are heating up again in 2026. Discover 5 high-growth biotech companies with strong pipelines, FDA catalysts, and explosive upside potential investors are watching. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-that-could-explode-in-2026/
0 · Reply
trichomy
trichomy Mar. 20 at 12:16 AM
$INMB $LLY $VRTX $REGN
0 · Reply
Latest News on REGN
Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Mar 24, 2026, 2:00 AM EDT - 4 days ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

SNY

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Mar 24, 2026, 2:00 AM EDT - 4 days ago

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 11, 2026, 1:52 PM EDT - 17 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Regeneron: Fairly Valued Now After A Stellar Upswing

Mar 11, 2026, 9:47 AM EDT - 17 days ago

Regeneron: Fairly Valued Now After A Stellar Upswing

Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

Mar 10, 2026, 10:59 PM EDT - 17 days ago

Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 10, 2026, 11:20 AM EDT - 18 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 4, 2026, 12:22 PM EST - 24 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)

Feb 28, 2026, 8:10 AM EST - 4 weeks ago

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)

AIO AMGN CVX EIC EOD EOS GAM

Why Dupixent Keeps Regeneron A Top Big Pharma Pick

Feb 27, 2026, 8:00 AM EST - 4 weeks ago

Why Dupixent Keeps Regeneron A Top Big Pharma Pick

Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

Feb 27, 2026, 7:03 AM EST - 4 weeks ago

Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

SNY

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

Feb 27, 2026, 7:00 AM EST - 4 weeks ago

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition

Feb 24, 2026, 1:47 PM EST - 4 weeks ago

Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition

SNY

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Feb 24, 2026, 9:30 AM EST - 4 weeks ago

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

Feb 24, 2026, 9:30 AM EST - 4 weeks ago

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

SNY

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Feb 19, 2026, 7:00 AM EST - 5 weeks ago

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

Feb 17, 2026, 7:08 AM EST - 5 weeks ago

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

OCUL

Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells

Feb 13, 2026, 5:45 AM EST - 6 weeks ago

Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells

ASML BABA BEKE BEPC GOOG GOOGL INCY

Regeneron Announces Investor Conference Presentations

Feb 11, 2026, 4:05 PM EST - 6 weeks ago

Regeneron Announces Investor Conference Presentations

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

Feb 10, 2026, 7:00 AM EST - 6 weeks ago

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

Feb 2, 2026, 12:13 PM EST - 7 weeks ago

These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

Feb 2, 2026, 7:00 AM EST - 7 weeks ago

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

Regeneron: Expect Double-Digit Growth In 2026

Jan 31, 2026, 8:33 AM EST - 2 months ago

Regeneron: Expect Double-Digit Growth In 2026

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript

Jan 30, 2026, 3:10 PM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript

Regeneron bets added cholesterol benefit will help its obesity drug stand out

Jan 30, 2026, 12:42 PM EST - 2 months ago

Regeneron bets added cholesterol benefit will help its obesity drug stand out

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Jan 30, 2026, 10:56 AM EST - 2 months ago

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Regeneron beats quarterly profit estimates on Dupixent strength

Jan 30, 2026, 7:37 AM EST - 2 months ago

Regeneron beats quarterly profit estimates on Dupixent strength

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Jan 30, 2026, 6:30 AM EST - 2 months ago

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Jan 30, 2026, 4:10 AM EST - 2 months ago

Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026

Jan 23, 2026, 3:25 PM EST - 2 months ago

Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026

Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

Jan 21, 2026, 12:05 PM EST - 2 months ago

Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:16 PM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Final Trades: Capital One, UnitedHealth, Regeneron and Alibaba

Jan 12, 2026, 1:30 PM EST - 2 months ago

Final Trades: Capital One, UnitedHealth, Regeneron and Alibaba

BABA COF UNH

Regeneron Just Moved From Underperform To Buy - Here's Why

Jan 7, 2026, 4:18 PM EST - 2 months ago

Regeneron Just Moved From Underperform To Buy - Here's Why

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

Dec 23, 2025, 1:00 AM EST - 3 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

SNY

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Dec 23, 2025, 1:00 AM EST - 3 months ago

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 4:05 PM EST - 3 months ago

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Regeneron: The Turnaround Is Gaining Steam

Dec 20, 2025, 9:30 AM EST - 3 months ago

Regeneron: The Turnaround Is Gaining Steam

Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv

Dec 10, 2025, 1:31 PM EST - 3 months ago

Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv

BKNG FISV GD

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript

Dec 10, 2025, 12:42 PM EST - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript

Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial

Dec 10, 2025, 12:20 PM EST - 3 months ago

Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial

Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?

Dec 8, 2025, 2:46 PM EST - 3 months ago

Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Dec 7, 2025, 4:30 PM EST - 3 months ago

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Regeneron's experimental therapy combo effective in untreated cancer patients

Dec 6, 2025, 9:33 AM EST - 4 months ago

Regeneron's experimental therapy combo effective in untreated cancer patients

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 2:13 PM EST - 4 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 4:53 PM EST - 4 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Dec 1, 2025, 7:00 AM EST - 4 months ago

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Nov 25, 2025, 1:00 AM EST - 4 months ago

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Nov 25, 2025, 1:00 AM EST - 4 months ago

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

SNY

This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead

Nov 21, 2025, 11:05 AM EST - 4 months ago

This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead

LLY

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

Nov 20, 2025, 11:52 AM EST - 4 months ago

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

Quantumup
Quantumup Mar. 27 at 12:44 PM
H.C. Wainwright reiterated $OCUL Buy/$21 $KOD $EYPT $REGN RHHBY $SRZN Here's what H.C. Wainwright had to say in its note: https://x.com/Quantumup1/status/2037510171836960935?s=20
0 · Reply
Iwannagofast1
Iwannagofast1 Mar. 27 at 4:07 AM
$REGN Hey @Johny34211 where you been hiding lil buddy? We’re at $754 through all the BS war stuff. You still living under your tiny little boulder ya donkey ? I’m still up $266 dollars a share on my second buy.
0 · Reply
SparkyReturns
SparkyReturns Mar. 26 at 6:59 PM
$BTC Public service announcement. I love BTC and these big pharma names, but here's one to check out. Up 30% and climbing. ICU Just getting started. 9 Million Market Cap. TAM in the Billions. [Read those 2 lines again] Cures the sickest of the sick. Will become standard of care in every ICU in the country. Happy hunting. $REGN $AMGN $VKTX $BMY
0 · Reply
OffHisGame88
OffHisGame88 Mar. 26 at 3:22 PM
$REGN 33% since and counting. Cheap
0 · Reply
prismmarketview
prismmarketview Mar. 25 at 2:20 PM
Gene therapy isn’t dead—it’s moving to the inner ear. Local AAV dosing for hereditary deafness cuts liver risk and COGS, and the market could top $1B by 2033. Watch $LLY and $REGN as first movers in otoferlin programs. https://prismmarketview.com/from-silence-to-signal-gene-therapies-target-hereditary-hearing-loss/
0 · Reply
Quantumup
Quantumup Mar. 24 at 12:59 PM
H.C. Wainwright⬆️ $SRZN PT to $36/reiterated at Buy. $EYPT $OCUL $FDMT $REGN RHHBY KOD Here's what H.C. Wainwright had to say in its note: https://x.com/Quantumup1/status/2036427176845640179?s=20
0 · Reply
Mnpois
Mnpois Mar. 22 at 4:11 PM
$REGN what about renergen $ASPI lol
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 22 at 3:56 PM
$REGN Regeneron Pharmaceuticals (NASDAQ: REGN) is proving that diversification can be a major advantage in biotech. With strong revenues, multiple blockbuster drugs, and a growing pipeline, this stock stands out in a volatile sector. https://biotechhealthx.com/biotech-news/heres-why-you-must-invest-in-regeneron-pharmaceuticals-regn-before-its-too-late/
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 22 at 3:21 PM
$AXSM $BNTX $EXEL $REGN $VRTX Biotech stocks are heating up again in 2026. Discover 5 high-growth biotech companies with strong pipelines, FDA catalysts, and explosive upside potential investors are watching. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-that-could-explode-in-2026/
0 · Reply
trichomy
trichomy Mar. 20 at 12:16 AM
$INMB $LLY $VRTX $REGN
0 · Reply
ProKnifeCatcher87
ProKnifeCatcher87 Mar. 19 at 8:41 PM
$REGN today 20 dma just hit 50 dma $737 strong technical here 683,657 …, 587
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 19 at 3:33 PM
$REGN Hedges just doing the rinse and repeat here still.
0 · Reply
cubie
cubie Mar. 17 at 8:00 PM
$REGN
1 · Reply
judgeyoung2
judgeyoung2 Mar. 17 at 7:54 PM
$REGN @cubie anything interesting here?
1 · Reply
PB09
PB09 Mar. 16 at 11:51 PM
$BCRX $TKD.X $VRTX $REGN $ALNY
0 · Reply
Quantumup
Quantumup Mar. 16 at 12:48 PM
Guggenheim reiterated Top Pick $EYPT Buy; $68 $OCUL $REGN RHHBY $SRZN KOD $FDMT Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2033524889840189801?s=20
0 · Reply
UndSchwung
UndSchwung Mar. 16 at 8:46 AM
$NVAX All fans of $BIIB $REGN $GILD $VRTX $NVAX is the next in line to enter the biotech unicorn club 🦄 Matrix-M for immunotherapy
0 · Reply
roblake29
roblake29 Mar. 13 at 3:29 PM
$REGN My latest on this company. Buy rating maintained. Read why here: https://seekingalpha.com/article/4881030-regeneron-fairly-valued-now-after-a-stellar-upswing
0 · Reply
REDBEAR
REDBEAR Mar. 13 at 2:45 AM
$BSX reminds me of when I made a ton of money with $REGN going down. We will do the same here.
0 · Reply
Bates333
Bates333 Mar. 12 at 7:29 PM
$REGN out
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 12 at 7:01 PM
$REGN is this really necessary for this drop? I'm not sure who the MM is on this, but this getting old.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 12 at 7:20 AM
$REGN trading at $774.66, with highest at $812.27 and lowest at $483.07. Average volume stands at 1,057,513, recent volume around 405,200.
0 · Reply